Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (csu) in adults and adolescents aged 12 years and older accepted for fda review

More than 300,000 people in the u.s. suffer from csu that is inadequately controlled by antihistamines more than 300,000 people in the u.s. suffer from csu that is inadequately controlled by antihistamines

REGN Ratings Summary

REGN Quant Ranking